drugset / Trial / NCT01057862

Investigation of Naltrexone for Pathological Gambling

NCT01057862

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The investigators plan to investigate the safety, tolerability, and efficacy of the opioid antagonist naltrexone in Pathological Gambling. We hypothesize that naltrexone will be superior to placebo in reducing gambling urges and behavior, when combined with adjuvant non-pharmacological treatment as usual.

Timeline

Start
2009-02
Primary completion
2016-02
Completion
2017-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Naltrexone Small molecule 50 mg Oral

Indications